(AOF) – Quantum Genomics announces that it has entered into exclusive negotiations with a view to a merger with ExactCure, a French company developing an artificial intelligence device making it possible to adapt the taking of medications to the profile of each individual. The entity resulting from the merger would become one of the first Digital Health companies listed on Euronext Growth. The merger of Quantum Genomics and ExactCure will notably accelerate the deployment of the personalized drug simulation system.
The acceleration will target medical solution providers, health insurance companies and pharmaceutical laboratories. A buyout could also accelerate the implementation of the system, which will go from 5,200 simulated medications to 10,000 simulated medications, and make it possible to integrate a functionality for detecting multi-drug interactions, a major issue during multiple prescriptions.
The ExactCure device makes it possible to create a digital twin for each patient based on a certain number of characteristics specific to each patient (age, weight, sex, kidney function, liver function, genetic mutations, treatments).
This digital twin makes it possible to simulate the behavior that the drug will have when taken by the patient (blood concentration, pharmacokinetics and pharmacodynamics, interactions with other drugs). So, when a patient takes an anti-inflammatory at noon, their digital twin predicts that in their specific case, the treatment will be effective at 12:20 p.m., will reach maximum effectiveness at 1:30 p.m. and will be eliminated at 6:30 p.m.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.